Stimpson Stephen A, Leonard Michael S, Clifton Lisa G, Poole James C, Turner Scott M, Shearer Todd W, Remlinger Katja S, Clark Richard V, Hellerstein Marc K, Evans William J
Muscle Metabolism Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKline, Research Triangle Park, NC, 27709, USA,
J Cachexia Sarcopenia Muscle. 2013 Jun 25;4(3):217-23. doi: 10.1007/s13539-013-0110-1.
We recently validated in cross-sectional studies a new method to determine total body creatine pool size and skeletal muscle mass based on D-creatine dilution from an oral dose and detection of urinary creatinine enrichment by isotope ratio mass spectrometry (IRMS). Routine clinical use of the method in aging and disease will require repeated application of the method, with a more widely available technology than IRMS, to enable determination of change in skeletal muscle mass in longitudinal studies. We therefore adapted the method to liquid chromatography-tandem mass spectrometry (LC-MS/MS) technology, and sought to establish proof of concept for the repeated application of the method in a longitudinal study. Because the turnover of creatine is slow, it was also critical to determine the impact of background enrichment from an initial dose of oral D-creatine on subsequent, longitudinal measurements of change in muscle mass.
Rats were given an oral tracer dose of D-creatine (1.0 mg/kg body weight) at 10 and 17 weeks of age. LC-MS/MS was used to determine urinary D-creatine, and urinary D-creatinine enrichment, at time intervals after D-creatine administration. Total body creatine pool size was calculated from urinary D-creatinine enrichment at isotopic steady state 72 h after administration of D-creatine tracer.
At 10 weeks of age, rat lean body mass (LBM) measured by quantitative magnetic resonance correlated with creatine pool size (r = 0.92, P = 0.0002). Over the next 7 weeks, the decline in urinary D-creatinine enrichment was slow and linear, with a rate constant of 2.73 ± 0.06 %/day. Subtracting background urinary D-creatinine enrichment from the elevated enrichment following a second dose of D-creatine at 17 weeks permitted repeat calculations of creatine pool size. As at 10 weeks, 17-week LBM correlated with creatine pool size (r = 0.98, P <0.0001). In addition, the change in creatine pool size was correlated with the change in LBM during the 7 weeks of rat growth between measurements (r = 0.96, P <0.0001).
The LC-MS/MS-based D-creatine dilution method can be applied repeatedly to measure total body creatine skeletal muscle mass change in longitudinal study.
我们最近在横断面研究中验证了一种新方法,该方法基于口服剂量的D-肌酸稀释以及通过同位素比率质谱法(IRMS)检测尿肌酐富集来确定全身肌酸池大小和骨骼肌质量。在衰老和疾病的常规临床应用中,该方法需要重复应用,且需要一种比IRMS更广泛可用的技术,以便在纵向研究中确定骨骼肌质量的变化。因此,我们将该方法应用于液相色谱-串联质谱(LC-MS/MS)技术,并试图在纵向研究中建立该方法重复应用的概念验证。由于肌酸的周转缓慢,确定口服D-肌酸初始剂量的背景富集对随后肌肉质量变化的纵向测量的影响也至关重要。
在10周龄和17周龄时给大鼠口服示踪剂量的D-肌酸(1.0mg/kg体重)。在给予D-肌酸后,通过LC-MS/MS在不同时间间隔测定尿D-肌酸和尿D-肌酐富集情况。根据给予D-肌酸示踪剂72小时后同位素稳态时的尿D-肌酐富集情况计算全身肌酸池大小。
在10周龄时,通过定量磁共振测量的大鼠去脂体重(LBM)与肌酸池大小相关(r = 0.92,P = 0.0002)。在接下来的7周内,尿D-肌酐富集的下降缓慢且呈线性,速率常数为2.73±0.06%/天。从17周时第二次给予D-肌酸后升高的富集中减去背景尿D-肌酐富集,允许重复计算肌酸池大小。与10周时一样,17周龄的LBM与肌酸池大小相关(r = 0.98,P <0.0001)。此外,在两次测量之间大鼠生长的7周内,肌酸池大小的变化与LBM的变化相关(r = 0.96,P <0.0001)。
基于LC-MS/MS的D-肌酸稀释方法可在纵向研究中重复应用,以测量全身肌酸骨骼肌质量变化。